{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:45:06Z","timestamp":1787013906032,"version":"build-2736575974"},"reference-count":31,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CIHR PJT\u2010153275"],"award-info":[{"award-number":["CIHR PJT\u2010153275"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP 1122332"],"award-info":[{"award-number":["APP 1122332"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Drug regulators issue safety advisories to warn clinicians and the public about new evidence of harmful effects of medicines. It is unclear how often these messages are covered by the media. Our aim was to analyse the extent of media coverage of two medicines that were subject to safety advisories from 2007 to 2016 in Australia, Canada, the United Kingdom and the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two medicines widely used to treat mental health or physical conditions were selected: citalopram and denosumab. Media reports were identified by searching LexisNexis and Factiva. Reports were included if they stated at least one health benefit or harm. A content analysis of the reports was conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 195 media reports on citalopram and 239 on denosumab were included. For citalopram, 43.1% (84\/195) of the reports mentioned benefits, 85.6% (167\/195) mentioned harms and 9.7% (19\/195) mentioned the harm described in the advisories (cardiac arrhythmia). For denosumab, 94.1% (225\/239) of the reports mentioned benefits and 39.7% (95\/239) mentioned harms. The harms described in the advisories were rarely mentioned: 10.9% (26\/239) of the reports mentioned osteonecrosis and \u22645% mentioned any of the other harms (atypical fractures, hypocalcaemia, serious infections and dermatologic reactions).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We found limited media coverage of the harms highlighted in safety advisories. Almost two\u2010thirds of the media stories on denosumab did not include any information about harms, despite the many advisories during this time frame. Citalopram coverage covered harms more often but rarely mentioned cardiac arrhythmias. These findings raise questions about how to better ensure that regulatory risk communications reach the general public.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.14255","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:58:51Z","timestamp":1581987531000},"page":"1416-1429","source":"Crossref","is-referenced-by-count":6,"title":["Media coverage of drug regulatory agencies' safety advisories: A case study of citalopram and denosumab"],"prefix":"10.1111","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8413-0440","authenticated-orcid":false,"given":"Alice","family":"Fabbri","sequence":"first","affiliation":[{"name":"Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"O'Keeffe","sequence":"additional","affiliation":[{"name":"Institute for Musculoskeletal Health, Sydney School of Public Health, Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Moynihan","sequence":"additional","affiliation":[{"name":"Institute for Evidence\u2010Based Healthcare Bond University  Gold Coast Queensland Australia"},{"name":"Sydney School of Public Health, Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"M\u00f8lleb\u00e6k","sequence":"additional","affiliation":[{"name":"Copenhagen Centre for Regulatory Science, Department of Pharmacy University of Copenhagen  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annim","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bhasale","sequence":"additional","affiliation":[{"name":"Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorri","family":"Puil","sequence":"additional","affiliation":[{"name":"Department of Anaesthesiology, Pharmacology, and Therapeutics, Faculty of Medicine University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Mintzes","sequence":"additional","affiliation":[{"name":"Charles Perkins Centre and School of Pharmacy, Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,3,20]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e318245a160"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1539-6924.2008.01024.x"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.2307\/3350088"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-3-200402030-00015"},{"issue":"9","key":"e_1_2_13_6_1","first-page":"1133","article-title":"Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs","volume":"168","author":"Cassels A","year":"2003","journal-title":"CMAJ"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200006013422206"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001266"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-100"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.0294"},{"key":"e_1_2_13_11_1","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module XV \u2013 Safety communication. 26 July2012. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-module-xv-safety-communication-rev-1_en.pdf. (Accessed October 2019)"},{"key":"e_1_2_13_12_1","unstructured":"Medicines and Healthcare products Regulatory Agency.Medicines & Medical Devices Regulation: what you need to know. April2008."},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4762"},{"key":"e_1_2_13_14_1","unstructured":"Xgeva INN\u2010denosumab. Summary of Product Characteristics. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xgeva-epar-product-information_en.pdf"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_2_13_16_1","unstructured":"LifeWatch. The Canadian Press \u2013 Broadcast wire. 31 January2012."},{"key":"e_1_2_13_17_1","unstructured":"SmithJL.Are we hooked on happy pills? Sunday Telegraph Magazine \u201cSeven\u201d. 15 July2012."},{"key":"e_1_2_13_18_1","unstructured":"AshleyB.Bone\u2010building medications; Ask the Doctors. The Capital (Annapolis). 14 June2017."},{"key":"e_1_2_13_19_1","unstructured":"Denosumab improves low bone mineral density in men. Reuters Health Medical News. 6 July2012."},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/10810730.2016.1266717"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2017.07.011"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000290"},{"key":"e_1_2_13_23_1","unstructured":"BlackburneR GarrisisD.Osteoporosis: addressing the unmet need. American Pharmaceutical Review December 26 2018."},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13729-4"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.21.2856"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/003335490512000215"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2008.01.010"},{"key":"e_1_2_13_28_1","doi-asserted-by":"crossref","unstructured":"LundhA LexchinJ MintzesB SchrollJB BeroL.Industry sponsorship and research outcome. Cochrane Database Syst Rev.2017;2:Mr000033.","DOI":"10.1002\/14651858.MR000033.pub3"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152301"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1369-7625.2003.00228.x"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.2196\/publichealth.7823"},{"key":"e_1_2_13_32_1","unstructured":"MoynihanR.A tipsheet for reporting on drugs devices and medical technologies. Available from:https:\/\/www.commonwealthfund.org\/sites\/default\/files\/documents\/___media_files_publications_other_2004_sep_tipsheet__for_reporting_on_drugs__devices_and_medical_technologies_moynihan_tipsheet_pdf.pdf"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.14255","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14255","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14255","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14255","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T06:16:55Z","timestamp":1692771415000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/bcp.14255"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14255","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,20]]}}}